Inotiv (NOTV) Expected to Announce Quarterly Earnings on Wednesday

Inotiv (NASDAQ:NOTV - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $123.97 million for the quarter.

Inotiv (NASDAQ:NOTV - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.10). Inotiv had a negative net margin of 25.40% and a negative return on equity of 15.41%. On average, analysts expect Inotiv to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Inotiv Stock Performance

Shares of NOTV traded up $0.01 during mid-day trading on Monday, reaching $2.04. The company had a trading volume of 198,485 shares, compared to its average volume of 560,656. The stock has a 50 day moving average of $2.40 and a two-hundred day moving average of $3.27. Inotiv has a 52-week low of $1.15 and a 52-week high of $6.48. The stock has a market capitalization of $68.78 million, a P/E ratio of -0.44 and a beta of 4.03. The company has a quick ratio of 1.28, a current ratio of 1.57 and a debt-to-equity ratio of 2.31.

Insider Activity

In other Inotiv news, CEO Robert Jr. Leasure sold 73,617 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $3.82, for a total transaction of $281,216.94. Following the sale, the chief executive officer now directly owns 956,592 shares in the company, valued at $3,654,181.44. This represents a 7.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 81,439 shares of company stock valued at $312,475 in the last 90 days. Company insiders own 7.80% of the company's stock.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.